Get the Stockscreener App
4.52
1.74%
-0.08
Pre-market:
3.80
-0.72
-15.93%
Onkure Therapeutics Inc stock is traded at $4.52, with a volume of 95,002.
It is down -1.74% in the last 24 hours and up +5.36% over the past month.
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure-based drug design platform to develop a pipeline of drug candidates aimed at optimizing efficacy and tolerability. The company has multiple programs focused on targeting oncogenic PI3Kα. Its flagship program is OKI-219. The company operates in one operating segment: clinical research.
See More
Previous Close:
$4.60
Open:
$4.49
24h Volume:
95,002
Relative Volume:
0.34
Market Cap:
$185.69M
Revenue:
-
Net Income/Loss:
$-59.52M
P/E Ratio:
-1.0261
EPS:
-4.4049
Net Cash Flow:
$-51.87M
1W Performance:
-13.41%
1M Performance:
+5.36%
6M Performance:
+50.67%
1Y Performance:
+80.08%
1-Day Range:
$4.41
$4.70
1-Week Range:
$4.41
$5.38
52-Week Range:
$1.70
$5.38
Onkure Therapeutics Inc Stock (OKUR) Company Profile
Name
Onkure Therapeutics Inc
Sector
Industry
Phone
(720) 307-2892
Address
6707 WINCHESTER CIRCLE, SUITE 400, BOULDER
Compare OKUR vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OKUR
Onkure Therapeutics Inc
|
4.52 | 185.69M | 0 | -59.52M | -51.87M | -4.4049 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Onkure Therapeutics Inc Stock (OKUR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-30-25 | Initiated | Evercore ISI | Outperform |
| Dec-05-24 | Initiated | Leerink Partners | Outperform |
| Oct-10-24 | Initiated | Oppenheimer | Outperform |
| Dec-15-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-15-23 | Downgrade | Jefferies | Buy → Hold |
| Dec-15-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Dec-14-23 | Downgrade | BofA Securities | Buy → Underperform |
| Dec-14-23 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Dec-14-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Dec-14-23 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-14-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Nov-15-23 | Initiated | William Blair | Outperform |
| Aug-28-23 | Initiated | H.C. Wainwright | Buy |
| Jul-03-23 | Initiated | BofA Securities | Buy |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jan-27-22 | Initiated | Robert W. Baird | Outperform |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-22-21 | Initiated | Ladenburg Thalmann | Buy |
| May-04-21 | Initiated | Jefferies | Buy |
| May-04-21 | Initiated | Piper Sandler | Overweight |
| May-04-21 | Initiated | SVB Leerink | Outperform |
View All
Onkure Therapeutics Inc Stock (OKUR) Latest News
[10-Q] OnKure Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
OnKure (Nasdaq: OKUR) lifts cash to $192.1 million after raise - Stock Titan
OnKure bets on 2 PI3K drugs for breast cancer and vascular anomalies - Stock Titan
OnKure Therapeutics Reports First Quarter 2026 Financial Results - Yahoo! Finance Canada
[EFFECT] OnKure Therapeutics, Inc. SEC Filing - Stock Titan
Aclarion reports cash runway to ops into late 2027 - BizWest
OnKure Therapeutics (OKUR) price target decreased by 15.13% to 20.60 - MSN
OnKure Therapeutics (OKUR) Projected to Post Quarterly Earnings on Tuesday - MarketBeat
OnKure Therapeutics prices $150M oversubscribed private placement - MSN
What top holdings OnKure Therapeutics (OKUR)? (Smart Money Active) 2026-04-27Earnings Beat Stocks - Newser
OKUR (OnKure Therapeutics) reports narrower Q4 2025 loss than estimates, shares drop 2.04 percent in trading. - Newser
Short Interest in OnKure Therapeutics, Inc. (NASDAQ:OKUR) Drops By 57.6% - MarketBeat
OnKure Therapeutics (OKUR) Price Target Decreased by 10.00% to 27.54 - MSN
OnKure Therapeutics (NASDAQ: OKUR) registers 36.1M shares for resale - Stock Titan
[DEF 14A] OnKure Therapeutics, Inc. Definitive Proxy Statement - Stock Titan
OnKure Therapeutics (OKUR) Stock Bollinger Bands (Risk Aversion) 2026-04-20Small Cap Breakout - Xã Thanh Hà
OnKure Therapeutics (OKUR) Stock Opening VWAP (Spikes) 2026-04-18Stock Distribution - Cổng thông tin điện tử tỉnh Lào Cai
What date does OnKure Therapeutics, Inc.'s (OKUR) report EarningsEarnings Calendar & Announcement - Zacks Investment Research
Short Interest in OnKure Therapeutics, Inc. (NASDAQ:OKUR) Increases By 1,958.6% - MarketBeat
Revenue Check: Whats the profit margin of OnKure Therapeutics Inc2026 Volume Leaders & Growth-Oriented Investment Plans - baoquankhu1.vn
Growth Recap: Is Vistra Corp gaining market shareQuarterly Trade Summary & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
OKUR SEC FilingsOnKure Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
Access Industries (OKUR) discloses 19.99% OnKure stake and board right - Stock Titan
StepStone affiliates report 2.66M shares in OnKure (NASDAQ: OKUR) - Stock Titan
RA Capital group reports 9.99% stake in OnKure (NASDAQ: OKUR) - Stock Titan
Trails Edge holds 6.0% of OnKure (NASDAQ: OKUR) after private placement - Stock Titan
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Trading Recap: Whats the profit margin of OnKure Therapeutics Inc2026 Biggest Moves & AI Driven Price Forecasts - baoquankhu1.vn
LifeSci Capital Maintains OnKure Therapeutics(OKUR.US) With Buy Rating, Cuts Target Price to $16 - 富途牛牛
Is OnKure Therapeutics (OKUR) Stock Safe to Buy Now | Price at $4.39, Up 2.33%Stock Idea Sharing Hub - UBND thành phố Hải Phòng
Breakouts Watch: Can OnKure Therapeutics Inc deliver consistent EPS growthDay Trade & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
OnKure (OKUR) CEO Nicholas Saccomano awarded 330,000 stock options - Stock Titan
OnKure (OKUR) CFO granted 110,000 stock options at $4.07 - Stock Titan
OnKure Therapeutics (OKUR) awards 110,000 options to Chief Scientific Officer - Stock Titan
OnKure (OKUR) grants CMO 110,000 stock options at $4.07 strike - Stock Titan
OnKure (OKUR) director receives 15,300 stock options at $4.14 strike price - Stock Titan
OnKure Therapeutics (OKUR) director Liam Ratcliffe submits Form 3 insider report - Stock Titan
Acorn funds and Anders Hove disclose stakes in OnKure (NASDAQ: OKUR) up to 9.5% - Stock Titan
OKUR Stock Analysis: OnKure Therapeutics Inc. Biotech 1.69% Dip at $4.07 Trading Level - Cổng thông tin điện tử tỉnh Tây Ninh
Leerink cuts OnKure stock price target on strategic shift By Investing.com - Investing.com Canada
Leerink cuts OnKure stock price target on strategic shift - investing.com
OnKure Announces $150M Private Placement and Board Changes - TipRanks
OnKure elects Dr. Liam Ratcliffe as director under Lead Investor designation - TradingView — Track All Markets
OnKure (NASDAQ: OKUR) secures $150M private placement and refocuses PI3Kα pipeline - Stock Titan
Panic Selling: Whats the profit margin of OnKure Therapeutics IncTake Profit & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
OnKure Therapeutics Sees Volatile Trading Amid Recent Developments - timothysykes.com
OKUR Shares Face Turbulence Amid Financial Downturn - StocksToTrade
OnKure Therapeutics Inc. Sees Variable Performance Amid Market Fluctuations - timothysykes.com
Onkure Therapeutics Inc Stock (OKUR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):